Clinical trials
Retinopathy clinical trials
Below are recruiting retinopathy clinical trials, each written for real people, not researchers. We’re tracking 115 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07236879Recruiting
AI eye test for diabetes patients in primary care
This trial uses an artificial intelligence (AI) system to check for diabetic eye disease (retinopathy) during your regular doctor visit. It aims to detect problems early so you can get treatment sooner.
Porto Alegre, Rio Grande do SulAges 18 years+ - NCT06701721RecruitingPhase 1
Study of THN391 eye injection for diabetic macular edema
This trial tests an experimental eye injection called THN391 for people with diabetic macular edema, a condition that causes vision loss due to swelling in the back of the eye. The study aims to see if the treatment is safe and may help improve vision.
Parramatta, New South WalesAges 18–80 - NCT07259928RecruitingPhase 2
Testing ANXV for diabetic retinopathy or retinal vein occlusion
This trial tests a new drug called ANXV (Annexin A5) to see if it is safe and can help people with diabetic retinopathy or a recent retinal vein occlusion. The goal is to reduce eye damage and improve vision.
LondonAges 18 years+ - NCT07296952Recruiting
Improving transportation for diabetic retinopathy patients
This study tests a new way to help people with diabetic retinopathy get to their eye appointments. It aims to make transportation easier for patients who have Medicaid insurance.
Chicago, IllinoisAges 18 years+ - NCT03161652RecruitingPhase 2
Levosulpiride for diabetic eye swelling and retinopathy
This Phase 2 study tests whether levosulpiride can improve changes in the retina in people with diabetic retinopathy and diabetic macular edema (eye swelling that can affect vision). It may help by targeting chemicals in the body that could affect eye tissue and inflammation.
Querétaro City, QuerétaroAges 40–69 - NCT07458516Recruiting
Observing eye disease progression in type 2 diabetes
This study closely follows people with type 2 diabetes who have early signs of diabetic retinopathy (damage to the retina from diabetes) to see how the condition changes over time. It does not test a new treatment but monitors the eye's health closely. It may be a good fit if you have diabetic retinopathy that does not need immediate treatment.
CoimbraAges 35–80 - NCT07468058Recruiting
Diabetic eye disease study in Da Nang
This study looks at how common diabetic retinopathy is and what factors increase the risk. It may help find better ways to prevent vision loss in people with diabetes.
Da NangAges 18 years+ - NCT07500324Recruiting
Searching for new markers in age-related eye diseases
This study looks for proteins in the blood and eye fluids that may help doctors better understand and monitor three common eye conditions: age-related macular degeneration, diabetic retinopathy, and retinal detachment. If you have one of these conditions, or if you are a healthy control with no retinal disease, you may be able to help by giving a small sample of blood or fluid from your eye during a routine procedure.
Roma, ItalyAges 18 years+ - NCT07520045Recruiting
Eye Injections for Diabetic Vision Loss: Two Treatment Comparison
This study compares two injectable medications (faricimab and biosimilar ranibizumab) used to treat diabetic retinopathy, a serious eye condition that can cause vision loss in people with diabetes. The trial will measure how well each medication works and track specific markers in your eye to understand treatment response.
OsijekAges 18 years+ - NCT07586787Recruiting
Early Vitrectomy vs Laser for Early Diabetic Eye Disease
This trial compares two treatments for early diabetic retinopathy—a condition where high blood sugar damages blood vessels in the eye. Researchers want to see if removing fluid from inside the eye (vitrectomy) works better than laser treatment to prevent vision loss.
Beijing, Beijing MunicipalityAges 18 years+ - NCT07588100RecruitingPhase 1
Safety study of RO7663498 eye injection for diabetic retinopathy
This is an early-stage safety study testing a new medicine injected directly into the eye to treat diabetic retinopathy (damage to blood vessels in the retina caused by diabetes). The study checks if the medicine is safe and how the body processes it.
Glendale, CaliforniaAges 18 years+ - NCT07634991RecruitingPhase 4
N-acetyl Cysteine for Diabetic Eye Disease
This study tests whether a supplement called N-acetyl cysteine can help slow or improve mild to moderate diabetic eye disease (diabetic retinopathy). The goal is to see if it's safe and effective for people with type 2 diabetes.
CairoAges 18–70 - NCT06191094Enrolling by invitationPhase 4
Vabysmo before eye surgery for bleeding in diabetes
This trial tests if an injection of Vabysmo (faricimab) given before surgery can help people with eye bleeding from diabetic retinopathy. It aims to reduce blood in the eye and improve surgery outcomes.
Aurora, ColoradoAges 18 years+ - NCT05132660Enrolling by invitationEarly Phase 1
Early eye treatment study for diabetic retinopathy
This early-phase study tests a treatment aimed at preventing or slowing early diabetic eye disease in people with mild, early changes. You may be considered if your diabetes is moderately controlled and your eye tests show early warning signs.
Decatur, GeorgiaAges 30–80 - NCT05074342Enrolling by invitation
Project Open study to improve eye screening for diabetes
This study uses health records to see how to increase eye exam screening for people with diabetes who may be at risk of diabetic retinopathy. It aims to help more people get timely eye checks to prevent vision problems.
Toronto, OntarioaAges 18 years+ - NCT06790784RecruitingPhase 3
Comparing faricimab plus laser vs. surgery for diabetic eye disease
This study compares two approaches to treat advanced diabetic eye disease (proliferative diabetic retinopathy): injections of faricimab plus laser, versus surgery (vitrectomy) with laser. It is for people with diabetes who need treatment for PDR and still have relatively good vision (20/100 or better) in the affected eye.
Huntington Beach, CaliforniaAges 18 years+ - NCT05704491Recruiting
AI screening for diabetic eye damage
This study tests an artificial intelligence (AI) screening method to detect diabetic retinopathy, a type of eye damage caused by diabetes. It may help find eye changes earlier, so treatment can be planned sooner.
DüsseldorfAges 18 years+ - NCT06749639RecruitingEarly Phase 1
Gene therapy trial for RDH12-related eye disease
This trial tests an injection called PUMCH-E101 for people with vision loss caused by changes in the RDH12 gene. The goal is to see if it is safe and if it can help improve vision.
Beijing, Beijing MunicipalityAges 8–45 - NCT06839443Recruiting
AI to detect hydroxychloroquine eye damage
This study uses artificial intelligence to look at eye images of people who have taken hydroxychloroquine for a long time. The goal is to better detect or predict early signs of retinal damage, so you can get the right care sooner.
PortugalAges 18–100 - NCT07149142Recruiting
AI eye screening for children with type 1 diabetes
This study tests if an artificial intelligence (AI) system can effectively screen for eye problems related to diabetes (retinopathy) in children. The goal is to find a faster, easier way to protect your child's vision.
Prague, Prague 5Ages 11–19 - NCT03135327Recruiting
Eye scans study to compare brain and eye health
This study uses detailed eye imaging to look for patterns that may go along with conditions like Alzheimer’s disease, memory problems, multiple sclerosis, or eye/vascular issues. It may help researchers better understand how eye findings relate to health and disease.
Miami, FloridaAges 18–99 - NCT03475173Recruiting
Non-invasive eye scans for healthy and specific retinal problems
This study tests new, non-invasive ways to measure how the retina (the light-sensing part of the eye) is structured and how well it works. It may help researchers better understand certain vision disorders and how to track them, without surgery or injections.
Iowa City, IowaAges 18–99 - NCT03713268Recruiting
Using a scan to guide eye surgery in real time
This trial tests whether a special eye scan (OCT) can help guide eye surgery during the operation. It may improve how surgeons see and target the exact eye structures they need to treat.
Durham, North CarolinaAges 4 weeks+ - NCT03752840Recruiting
Community eye-worker program in Nepal
This trial tests a village-based approach to bring eye care closer to older community members. If you live in the right area and are willing to participate, it may help improve access to eye screening and services.
San Francisco, CaliforniaAges 60 years+
Hear when a new Retinopathy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for retinopathy?
- Yes. Clin2 currently lists 115 recruiting retinopathy studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a retinopathy trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a retinopathy trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.